SAN DIEGO - The Trump administration is throwing its full support behind the use of medicines to treat people with opioid problems, and is opposing increasing tolerance of marijuana use by young people in part because that can lead to painkiller abuse, a top official said Friday.
“Medically assisted treatment is the standard of care for opioid use disorder,” said Elinore F. McCance-Katz, first assistant secretary for mental health and substance use with the Department of Health and Human Services.
Dr. McCance-Katz spoke Friday to thousands of psychiatrists and other health and social work professionals at the annual conference of the American Society of Addiction Medicine in San Diego.
Medicines like methadone, buprenorphine and naltrexone are used to help people who have addictions to opioids including heroin and fentanyl. The persistence of methadone and the emergence of buprenorphine as weapons in the battle against addiction is viewed with skepticism by supporters of strict abstinence from all narcotics.
Dr. McCance-Katz said that 11.5 million Americans misuse prescription opioids, which she characterized as “a huge issue.” She put the number of heroin users at 948,000 in 2016, up from an estimated 404,000 in 2002 and 828,000 in 2015.
Of the 2 million Americans with full-blown opioid use disorders, just 20 percent are getting treatment, she said. Of those getting treatment, only 37 percent are getting medicines including methadone, buprenorphine (commonly referred to by the brand name Suboxone) or naltrexone (usually the brand Vivitrol), she said.
Read More
Meanwhile fatal drug overdoses reached a record 63,000 in 2016, of which two-thirds were opioid-related.
“We’re starting to see some signs of progress, but we have a lot more work to do,” she said. On the to-do list: a “culture change” in the medical community, availability of anti-opioid medications in “all medical facilities,” better pay for addiction specialists, and technological improvements.
She called for development of long-acting injectable medicines to prevent opioid withdrawal symptoms while making it difficult for the patient to get high. She also wants to see more potent naloxone (sometimes referred to by the brand name Narcan), which reverses opioid overdoses, but is available only in concentrations sometimes too weak to negate the effects of powerful fentanyl or carfentanil."
Some of the opposition to medication-assisted treatment for opioid addiction is based on the reality that two of the primary drugs, methadone and buprenorphine, are opioids. Buprenorphine, in some of its forms, is difficult to abuse on its own, but can be harmful or deadly in combination with some other drugs.
Opioids and benzodiazepines like Xanax are "just a bad mix. Well, for some people, it's a bad mix," said Karen Gerlach, co-director of clinical and behavioral research at Pinney Associates, which has an office in Oakland, where she works, and is based in Bethesda, Md. Both drugs can slow breathing, and in combination with each other and sometimes with other drugs, they can stop respiration entirely, resulting in death.
Her Pittsburgh-based team has been working with 14 buprenorphine companies and the Food and Drug Administration to monitor the extent to which buprenorphine and benzodiazepines are being prescribed to the same patients, and the negative effects.
Presenting her findings at the ASAM conference, she said that more than half of prescribers surveyed had recommended both buprenorphine and benzodiazepines to the same patients. And in some samples of fatal overdoses in which the toxicology results included buprenorphine, more than half of the deceased had also used benzodiazepines prior to death.
"We monitor this very closely, because it's very concerning to us, the number of patients that we have that are on both medications," she said, adding that it's not surprising that doctors would prescribe benzodiazepines, which reduce anxiety, to people who are trying to recovery from addiction.
"It is an issue that [the FDA is] clearly paying attention to," she said. "They did recently come out with a notice to prescribers that they should be carefully monitoring patients who are on both of these medications because of the additional risk of potential overdose.
Some of the opposition to medication-assisted treatment for opioid addiction is based on the reality that two of the primary drugs, methadone and buprenorphine, are opioids. Buprenorphine, in some of its forms, is difficult to abuse on its own, but can be harmful or deadly in combination with some other drugs.
Opioids and benzodiazepines like Xanax are "just a bad mix. Well, for some people, it's a bad mix," said Karen Gerlach, co-director of clinical and behavioral research at Pinney Associates, which has an office in Oakland, where she works, and is based in Bethesda, Md. Both drugs can slow breathing, and in combination with each other and sometimes with other drugs, they can stop respiration entirely, resulting in death.
Her Pittsburgh-based team has been working with 14 buprenorphine companies and the Food and Drug Administration to monitor the extent to which buprenorphine and benzodiazepines are being prescribed to the same patients, and the negative effects.
Presenting her findings at the ASAM conference, she said that more than half of prescribers surveyed had recommended both buprenorphine and benzodiazepines to the same patients. And in some samples of fatal overdoses in which the toxicology results included buprenorphine, more than half of the deceased had also used benzodiazepines prior to death.
"We monitor this very closely, because it's very concerning to us, the number of patients that we have that are on both medications," she said, adding that it's not surprising that doctors would prescribe benzodiazepines, which reduce anxiety, to people who are trying to recovery from addiction.
"It is an issue that [the FDA is] clearly paying attention to," she said. "They did recently come out with a notice to prescribers that they should be carefully monitoring patients who are on both of these medications because of the additional risk of potential overdose.
Kelly J. Clark, president of the society, added that she wants research on the reasons why the medical treatments for opioid addiction aren’t being more widely adopted.
“Why aren’t people using it?” Dr. Clark asked. “What are the barriers?”
Both Dr. Clark and Dr. McCance-Katz said that they believe that marijuana should be decriminalized, but not legalized. They disagreed with arguments made by marijuana advocates that the spread of “pot” can reduce opioid addictions and overdoses.
“There is no such thing as medical marijuana from the standpoint of an addiction physician,” said Dr. Clark.
Dr. McCance-Katz cited research released in December showing what she called a “very substantial risk” for young marijuana users to develop opioid problems. She added that marijuana use, which is rising among minors, is associated with poor school performance, declining IQ, and early onset of some mental health problems.
“We want our children to be free of these kinds of adverse effects that result from marijuana exposure,” she said.
The conference continues through Sunday. The National Press Foundation is underwriting attendance by the Post-Gazette and 14 other news outlets.
Rich Lord: rlord@post-gazette.com



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.